Retinal Pigment Epithelium Cell Therapy for Geographic Atrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry-AMD lack effectiveness in slowing disease progression and restoring visual function, with existing measures failing to address the degeneration of retinal pigment epithelium cells and subsequent vision loss.
Innovation Solution
Administration of human embryonic stem cell-derived retinal pigment epithelium (RPE) cells to promote engraftment, integration, and survival in the ocular structure, slowing disease progression and improving visual acuity by secreting trophic factors and stabilizing retinal pigmentation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RPE cell therapy is administered to treat dry-AMD, then visual function preservation and disease progression slowing are improved, but treatment effectiveness and visual acuity restoration remain insufficient
Solution Approach 1:
The patent employs multiple advanced imaging parameters and functional assessments beyond traditional BCVA, including OCT-based morphological parameters (ellipsoid zone integrity, RPE layer thickness), microperimetry for retinal sensitivity mapping, and contrast sensitivity measurements. These parameter changes enable more sensitive detection of therapeutic effects and visual function changes that BCVA alone cannot capture.
Solution Approach 2:
The patent implements comprehensive monitoring protocols that provide feedback on treatment efficacy through repeated imaging assessments. By tracking multiple parameters over time (OCT scans, microperimetry, contrast sensitivity), the system provides detailed feedback on disease progression and treatment response, enabling adjustment of therapeutic strategies.
2Ease of operation
If traditional BCVA measurement is used to assess treatment efficacy, then ease of measurement is improved, but measurement precision and detection of visual function nuances are worsened
Solution Approach 1:
The patent segments visual function assessment into multiple distinct components: central acuity (BCVA), contrast sensitivity across different luminance levels, microperimetry for localized retinal sensitivity, and OCT-based structural assessments. This segmentation allows each parameter to be optimized for its specific measurement purpose while collectively providing comprehensive visual function evaluation.
Solution Approach 2:
The patent adds dimensional depth to visual assessment by incorporating spatial (OCT cross-sections), functional (microperimetry sensitivity maps), and physiological (contrast sensitivity curves) dimensions beyond the single-dimensional BCVA measurement. This multi-dimensional approach captures nuanced visual function changes that occur before BCVA deterioration.
3Measurement precision
If comprehensive visual function assessments are implemented, then measurement precision and disease detection are improved, but device complexity and assessment time are worsened
Solution Approach 1:
The patent integrates multiple assessment functions into a coordinated clinical protocol that uses standardized imaging platforms (OCT, fundus cameras) and established functional tests (microperimetry, contrast sensitivity). By leveraging existing multi-functional imaging equipment and standardized protocols, the system achieves comprehensive assessment without requiring entirely new specialized devices for each measurement type.
Data Source
AI summary
Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells.